Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Chen, Suning  [Clear All Filters]
2023
Li S, Ge J, Zhou S, Zhu W, Han Y, Chen S, Xue S, Wang Y, Qiu H, Wu X, et al. CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy bridging to allogeneic haematopoietic stem cell transplantation for B-cell acute lymphoblastic leukaemia delays platelet recovery and increases risks of cytomegalovirus and Epstein-Barr vir. Clin Transl Med. 2023;13(10):e1459.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, et al. Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2023;16(1):13.
Yu Z, Yao Y, Zhang Y, Chen J, Xu Y, Xue S, Qiu H, Tang X, Han Y, Chen S, et al. The efficacy of first salvage therapy determines the outcomes of adult patients with type 1 primary refractory acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2023.
Yu Z, Yao Y, Zhang Y, Chen J, Xu Y, Xue S, Qiu H, Tang X, Han Y, Chen S, et al. Outcomes of adult patients with type 1 primary refractory acute myeloid leukemia: a single center experience. Hematology. 2023;28(1):2212534.
Xiao J, Xie J, Zhou B, Liu Y, Lu J, Jiang A, Yao H, Qiu Q, Ding Z, Xue S, et al. RUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia. Leuk Lymphoma. 2023:1-11.
Zhang X, Gale RPeter, Liu B, Huang J, Zhang Y, Du X, Weng J, Li W, Xu N, Liu X, et al. Validation of the imatinib-therapy failure model. Leukemia. 2023.